Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T1795 |
Carfilzomib
卡非佐米,PR-171 |
Apoptosis; Proteasome; Autophagy | Apoptosis; Autophagy; Proteases/Proteasome; Ubiquitination |
Carfilzomib (PR-171) 是一种蛋白酶体抑制剂,与 20S 蛋白酶体的糜蛋白酶不可逆结合。Carfilzomib 具有抗肿瘤活性,可以用于治疗多发性骨髓瘤。 | |||
T18320 |
MC-Val-Cit-PAB-carfilzomib iodide
MC-Val-Cit-PAB-carfilzomib |
Others | Others |
MC-Val-Cit-PAB-carfilzomib is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADC), comprising the irreversible proteasome inhibitor carfilzomib, connected through the ADC linker MC-Val-Cit-PAB. | |||
T30806 |
CFLZ-567
|
||
CFLZ-567 is a key intermediate for making carfilzomib. | |||
T21342 |
CFLZ-171 TFA salt
|
||
CFLZ-171 is a key intermediate for the synthesis of carfilzomib. | |||
T80771 |
WRR139
|
||
WRR139为肽乙烯基砜类化合物,涉及诸如炎症与癌症等病症的生物学路径。该化合物同时作用于胞质酶N-聚糖酶1(NGLY1)与Nrf1,表现为抑制剂身份。WRR139可提升Carfilzomib对癌细胞的细胞毒效应。 |